Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease

American Journal of the Medical Sciences

Volumn 345, Issue 3, 2013, Pages 222-226

  Zhong, Yuan ^a   Zheng, Xueli ^a   Miao, Ya ^a   Wan, Lili ^a   Yan, Hong ^a   Wang, Beiyun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Apolipoprotein E; CYP2D6*10; Donepezil; Efficacy.

Indexed keywords

APOLIPOPROTEIN E4; CYTOCHROME P450 2D6; DONEPEZIL; APOLIPOPROTEIN E; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; COGNITION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ALLELE; BLOOD; CLINICAL TRIAL; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; COGNITION; CYTOCHROME P-450 CYP2D6; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; HUMANS; INDANS; MALE; MIDDLE AGED; MUTATION; NOOTROPIC AGENTS; PIPERIDINES; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

MLCS; MLOWN;

EID: 84874650979     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318255a8f9     Document Type: Article

References (32)

1. Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer's Disease. Curr Pharm Des 2004;10:231-51.
2. Hansen RA, Gartlehner G, Lohr KN, et al. Functional outcomes of drug treatment in Alzheimer's disease: a systematic review and metaanalysis. Drugs Aging 2007;24:155-67.
3. Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008;148:370-8.
4. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95.
5. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 1996;7:293-303.
6. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006:CD001190.
7. Pilotto A, Franceschi M, D'Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 2009;73:761-7.
8. Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol 2006;62: 721-6.
9. Ji L, Pan S, Wu J, et al. Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin Med J (Engl) 2002;115:1780-4.
10. Tateishi T, Chida M, Ariyoshi N, et al. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 1999;65:570-5.
11. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
12. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995;92:12260-4.
13. Almkvist O, Jelic V, Amberla K, et al. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebocontrolled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 2001;12:22-32.
14. Aerssens J, Raeymaekers P, Lilienfeld S, et al. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12: 69-77.
15. Babic T, Mahovic Lakusic D, Sertic J, et al. ApoE genotyping and response to galanthamine in Alzheimer's disease-a real life retrospective study. Coll Antropol 2004;28:199-204.
16. Yang Y-H, Wu S-L, Chou M-C, et al. Plasma concentration of donepezil to the therapeutic response of Alzheimer's disease in Taiwanese. J Alzheimers Dis 2011; 23:391-397.
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
18. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-4.
19. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-7.
20. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
21. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
22. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-45.
23. Seltzer B. Donepezil: a review. Expert Opin Drug Metab Toxicol 2005; 1:527-36.
24. Xie Z, Liao Q, Xu X, et al. Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun Mass Spectrom 2006;20:3193-8.
25. Cacabelos R, Llovo R, Fraile C, et al. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr Alzheimer Res 2007;4:479-500.
26. Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Expert Opin Pharmacother 2005;6:1967-1987.
27. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-295.
28. Harold D, Macgregor S, Patterson CE, et al. A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease[J]. Pharmacogenet Genomics 2006; 16:75-7.
29. Scacchi R, Gambina G, Moretto G, et al. Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine[J]. Am J Med Genet B Neuropsychiatr Genet 2009; 150B:502-7.
30. Farlow MR, Lahiri DK, Poirier J, et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 1998;50: 669-77.
31. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54: 2261-8.
32. Choi SH, Kim SY, Na HR, et al. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2008;25:445-50.